



Association between consumption frequency of honey and non-alcoholic fatty liver disease: results from a cross-sectional analysis based on the Tianjin Chronic Low-grade Systemic Inflammation and Health (TCLSIH) Cohort Study

Shunming Zhang¹, Xiaohui Wu^{2*}, Shanshan Bian³, Qing Zhang⁴, Li Liu⁴, Ge Meng^{1,5}, Zhanxin Yao^{1,6}, Hongmei Wu¹, Yeqing Gu¹, Yawen Wang¹, Shaomei Sun⁴, Xing Wang⁴, Ming Zhou⁴, Qiyu Jia⁴, Kun Song⁴ and Kaijun Niu^{1,4,7,8*}

¹Nutritional Epidemiology Institute and School of Public Health, Tianjin Medical University, Tianjin 300070, People's Republic of China

²College of Pharmacy, Tianjin Medical University, Tianjin 300192, People's Republic of China

³The Second Hospital of Tianjin Medical University, Tianjin 300052, People's Republic of China

⁴Health Management Centre, Tianjin Medical University General Hospital, Tianjin 300070, People's Republic of China

⁵Department of Toxicology and Sanitary Chemistry, School of Public Health, Tianjin Medical University, Tianjin 300050, People's Republic of China

⁶Tianjin Institute of Environmental & Operational Medicine, Tianjin 300070, People's Republic of China

⁷Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin 300070, People's Republic of China

⁸Center for International Collaborative Research on Environment, Nutrition and Public Health, Tianjin 300070, People's Republic of China

(Submitted 12 April 2020 – Final revision received 11 August 2020 – Accepted 11 August 2020 – First published online 17 August 2020)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. Recent evidence has suggested the protective effects of honey consumption against the metabolic syndrome, but the association between honey intake and NAFLD is still unclear. We investigated how the consumption frequency of honey was associated with NAFLD in the general population. This was a cross-sectional study of 21 979 adults aged 20–90 years. NAFLD was diagnosed based on the ultrasound-diagnosed fatty liver without significant alcohol intake and other liver diseases. Diet information, including consumption frequency of honey, was assessed by a validated 100-item FFQ. OR with 95 % CI were calculated by the binary logistic regression model, adjusting for confounding factors identified by the directed acyclic graph. Overall, 6513 adults (29.6 %) had NAFLD. Compared with participants consuming ≤ 1 time/week of honey, the multivariable OR of NAFLD were 0.86 (95 % CI 0.77, 0.97) for 2–6 times/week and 1.10 (95 % CI 0.95, 1.27) for ≥ 1 times/d ($P_{\text{for trend}} = 0.90$). The results were generally similar in subgroups of BMI at a cut-point of 24.0 kg/m² ($P_{\text{for interaction}} = 0.10$). In this large-scale study, consuming honey 2–6 times/week was inversely associated with NAFLD, whereas consuming honey ≥ 1 times/d had no association with NAFLD. These results need replication in other large-scale prospective studies.

Key words: Honey: Non-alcoholic fatty liver disease: Steatosis: China: Epidemiology

Non-alcoholic fatty liver disease (NAFLD) is an emerging public health problem and affects approximately 30 % of the global adult population^(1,2). Individuals with NAFLD have an increased risk of progression to non-alcoholic steatohepatitis, cirrhosis and hepatocellular carcinoma^(2,3). Moreover, NAFLD is a major risk factor for CVD, type 2 diabetes and chronic kidney disease⁽⁴⁾. Therefore, it is necessary to identify potentially modifiable factors to curb the increasing prevalence of NAFLD.

Honey is a natural sweet substance produced by honeybees from nectars of flowers, living plant secretions or excretions of plant-sucking insects on the living plants⁽⁵⁾. In China, honey is widely consumed as a food not only due to its unique taste and flavour but also due to a general understanding that it is a healthy food⁽⁶⁾. Honey contains polyphenol compounds, minerals, numerous vitamins, antioxidant enzymes and proteins^(5,7). Previous literature has documented that honey intake could

Abbreviations: DAG, directed acyclic graph; NAFLD, non-alcoholic fatty liver disease; TCLSIH, Tianjin Chronic Low-grade Systemic Inflammation and Health.

* **Corresponding authors:** Kaijun Niu, email nkj0809@gmail.com; Xiaohui Wu, email longhui804@163.com

protect against the metabolic syndrome by exerting anti-obesity, antidiabetic, hypolipidaemic and hypotensive activities⁽⁸⁾. A growing body of evidence also has shown that honey owns antioxidative and anti-inflammatory effects^(9,10), both of which play an important role in the development of NAFLD^(11,12). In addition, several randomised clinical trials suggest that honey intake could ameliorate insulin resistance, thereby preventing NAFLD^(13,14). Moreover, animal studies demonstrated that honey supplementation might reverse the formation of hepatic steatosis⁽¹⁵⁾. Despite these potential health benefits, honey is rich in fructose and glucose⁽¹⁶⁾; high fructose intake has been suggested to be a key factor that induces NAFLD^(17,18). Therefore, we hypothesised that honey intake might have a dual role in the development of NAFLD.

To our knowledge, studies have not examined the association between consumption frequency of honey and NAFLD in the general population. Therefore, we designed this large-scale study to investigate how the consumption frequency of honey is associated with NAFLD in the Tianjin Chronic Low-grade Systemic Inflammation and Health (TCLSIH) study.

Methods

Study population

The present study is a cross-sectional analysis of baseline data from the TCLSIH dataset, which is a large prospective dynamic cohort study evaluating the association between inflammation and chronic diseases among general Chinese adults living in Tianjin, China. The TCLSIH study design has been described in detail previously^(19,20). In brief, the study was established in 2007. All participants attended annual comprehensive health examinations. Liver ultrasound has been a part of our study protocol since 2010. Moreover, since May 2013, participants have been administered a questionnaire survey to assess diet and lifestyle factors. The survey response rate is above 93.7%. The TCLSIH study has been approved by the Institution Review Board of Tianjin Medical University, and all participants provided written informed consent.

In the present study, all participants who underwent abdominal ultrasound between January 2015 (when honey consumption collection information began) and December 2017 were included. During this study period, a total of 24 756 participants were included. We excluded participants with missing dietary data (*n* 969), participants with other liver diseases (chronic virus hepatitis, operations on the liver, autoimmune liver diseases, cirrhotic or alcoholic fatty liver disease) (*n* 928) and participants who had CVD (*n* 744) or cancer (*n* 136). Finally, 21 979 participants were included in the cross-sectional analysis (Fig. 1). Based on the prevalence of NAFLD in the Chinese population and on the principle of ten outcome events per variable, the sample size was calculated⁽²¹⁾. The sample size of 21 979 is large enough to provide adequate statistical power.

Diagnosis of non-alcoholic fatty liver disease

Abdominal ultrasound was performed by trained and certified technicians using a TOSHIBA SSA-660A ultrasound machine




Fig. 1. Flow diagram showing the process for the selection of eligible participants.

(Toshiba), with a 2–5 MHz curved array probe. Participants were considered to have fatty liver disease if at least two of the following abnormal findings of abdominal ultrasound existed: liver brightness, deep attenuation and vascular blurring⁽²²⁾. NAFLD was determined as the presence of fatty liver disease without significant alcohol intake (>210 g/week for men and >140 g/week for women) or any other causes (e.g. chronic hepatitis or autoimmune liver diseases)⁽²²⁾. Inter-observer variations for ultrasound NAFLD status (yes or no) were evaluated in 200 participants, and the kappa coefficient was 0.90 (*P* < 0.0001)⁽¹⁹⁾.

Assessment of dietary intake

Dietary information was collected using a validated 100-item semi-quantitative FFQ. Participants were asked to report their usual consumption frequency over the last month using seven frequency categories for foods ranging from ‘never or hardly ever’ to ‘≥2 times/d’ and eight frequency categories for beverages ranging from ‘almost never drink’ to ‘≥4 cups/d’. The intake of energy and nutrients was calculated using the FFQ data and the 2009 Chinese Food Composition Table⁽²³⁾. The reproducibility and validity of the FFQ were assessed in a random sample of 150 participants by comparing the data from two FFQ collected approximately 3 months apart and four 4-d weighed diet records (covering three non-consecutive weekdays and one weekend day). For the validation study, a random subsample of 150 TCLSIH study participants who had previously completed the first FFQ (FFQ1) were invited to participate. The participants for the validation study were randomly selected from different subgroups (age 20–30, 30–40, 40–50, 50–60, 60–70 and >70 years) of the TCLSIH study participants, and at least ten men and ten women were included in each of these subgroups. Participants were asked to complete four 4-d weighed diet records, approximately 3 months apart. The records began

3 months after completing the FFQ1. The four 4-d diet records documented all foods consumed covering three non-consecutive weekdays and one weekend day and excluded non-typical days (e.g. attending a wedding, banquets or temporary business trip). While they recorded their diet in this manner, we also administered four FFQ (3 months apart, FFQ2–FFQ5) to all consenting participants (n 150). Daily intake of the sixteen (four 4-d) dietary records was averaged and used as the representative weighed diet; FFQ1 was used as the reference to evaluate the FFQ validity. Although the reference period differed between FFQ1 (previous month) and 4-d diet records conducted in each season (representative of habitual intake during the year), we intended to assess whether a single FFQ during the previous month can represent habitual dietary intakes over a longer period (e.g. 1 year or more). This approach is similar to methods performed in a previous Japanese study⁽²⁴⁾. Reproducibility of the FFQ was assessed by comparing FFQ1 and FFQ2, collected approximately 3 months apart. Although it is possible that the process of recording diet might alter awareness of food intake and thus improve accuracy in completing the FFQ⁽²⁵⁾, it is unlikely that the diet records could have affected the completion of FFQ2. This is because FFQ2 was only completed after the first diet records started. Additionally, correlations between FFQ1 and FFQ5 were similar to correlations between FFQ1 and FFQ2. Spearman correlation coefficients between the FFQ1 and weighed diet records were energy intake = 0.49, nutrients = 0.35–0.54 and honey = 0.69. The energy-adjusted correlation coefficients between the FFQ1 and weighed diet records ranged from 0.39 to 0.72 for nutrients and 0.71 for honey. Spearman's rank correlation coefficients between the FFQ1 and FFQ2 were total energy = 0.68, food group (fruits, vegetables and beverages) = 0.62–0.79 and honey = 0.75. In this validation study, honey intake was expressed as g/d. For seasonal food intake, such as orange, hawthorn and watermelon, we inquired participants' intake in the previous month and in the natural mature season. Therefore, despite the FFQ only referring to the last month, long-term dietary intake of the participants could be inferred.

The FFQ included seven predefined frequency categories for honey consumption: almost never, <1 time/week, 1 time/week, 2–3 times/week, 4–6 times/week, 1 time/d and ≥ 2 times/d. In our study, a standard portion size (represented the 50th percentile of the weighed diet records) of honey was 18 g for men and 15 g for women⁽²⁶⁾. Based on the similar prevalence of NAFLD across categories of honey consumption frequency⁽²⁷⁾, we categorised the consumption frequency of honey as ≤ 1 time/week, 2–6 times/week and ≥ 1 times/d. Because most of the variation in intake of any food is explained by the frequency of its use⁽²⁵⁾, honey consumption frequency (rather than amount) was used as the main exposure variable in this study.

To measure overall diet quality, dietary patterns were derived by factor analysis with principal component based on the original ninety-nine foods/food groups listed in the FFQ (honey was excluded in the calculation). Varimax rotation was used to enhance the interpretability of factors. Three factors were retained according to the Scree plot, eigenvalues >1.0 and interpretability. Factors were named descriptively based on food items with high factor loading as follows: sweet food pattern (factor 1), healthy pattern (factor 2) and animal food pattern

(factor 3), similar to our previous findings⁽²⁰⁾. A higher factor score represents a higher food intake of that dietary pattern.

Assessment of covariates

Information on age, sex, smoking status, alcohol intake, education level, employment status, household income per month, family history of diseases (CVD, hypertension, hyperlipaemia and diabetes), self-reported history of diseases (hypertension, hyperlipaemia and diabetes) was assessed during annual health examinations through a self-administered questionnaire. Height and weight were measured with participants wearing light clothes and no shoes. BMI was calculated as weight (kg) divided by height squared (m^2). Waist circumference was measured using plastic tape at the level of umbilicus in standing position at the end of a gentle expiration. Physical activity was assessed using the short version of the International Physical Activity Questionnaire and was expressed as metabolic equivalents per week⁽²⁸⁾.

Blood pressure was measured at least two times using a validated semiautomatic oscillometer (A&D TM-2655). The measurement average was calculated to determine the final blood pressure value. Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, or self-reported hypertension⁽²⁹⁾. Plasma total cholesterol, TAG, LDL-cholesterol and HDL-cholesterol were measured in fasting blood samples using enzymatic methods. Hyperlipidaemia was defined as total cholesterol ≥ 5.17 mmol/l or TAG ≥ 1.7 mmol/l or LDL-cholesterol ≥ 3.37 mmol/l or taking antilipemic drugs⁽³⁰⁾. Fasting blood glucose was measured using the glucose oxidase method. Diabetes was defined according to the American Diabetes Association criteria⁽³¹⁾.

Statistical analysis

Normal distribution of continuous variables was assessed using quantile–quantile plots. Due to nonnormality, all the continuous variables were naturally log transformed. Baseline characteristics of the participants were presented as geometric means and 95 % CI for continuous variables and as percentages for categorical variables. Continuous variables were compared using ANCOVA, and categorical variables were compared using logistic regression analysis.

Binary logistic regression models were used to estimate the OR and 95 % CI for the association of honey consumption frequency with NAFLD. We determined potential confounders using a directed acyclic graph (DAG; Fig. 2)^(32,33). To select the minimally sufficient adjustment set, we used DAGitty, which is a popular web application for constructing DAG⁽³⁴⁾. Minimal sufficient adjustment sets for estimating the effect of honey on NAFLD included age, sex, BMI, smoking status, alcohol intake, socio-economic status, family history of disease, individual disease history, physical activity, total energy and diet pattern. We fitted three models. Model 1 was adjusted for age, sex and BMI. Model 2 was adjusted for age, sex, BMI, smoking status, alcohol intake, socio-economic status (including education level, employment status and household income per month), family history of disease (CVD, hypertension, hyperlipaemia and diabetes), individual disease history (hypertension, hyperlipaemia






Fig. 2. Direct acyclic graph (DAG) derived from previous literature and expert knowledge. Nodes represent variables and arrows represent causal associations. Honey is exposure, and non-alcoholic fatty liver disease (NAFLD) is outcome. SES, socio-economic status (including education level, employment status and household income per month).

and diabetes), physical activity and total energy intake. Model 3 (full model) was additionally adjusted for sweet food pattern score, healthy pattern score and animal food pattern score. Interactions between honey consumption frequency and confounding factors were tested by including cross-product terms in model 3. Moreover, we assessed multicollinearity in the final model using the variance inflation factor.

Due to importance of obesity in the development of NAFLD, we performed a subgroup analysis according to BMI (<24.0 or ≥ 24.0 kg/m²). The cut-point of 24.0 kg/m² was selected based on definitions of the Chinese Working Group on Obesity⁽³⁵⁾. In addition, a sensitivity analysis excluding all participants with significant alcohol intake (>210 g/week for men or >140 g/week for women) was conducted. We also assessed the association between honey consumption frequency and NAFLD based on different categorisations. Furthermore, we performed a sensitivity analysis with energy-adjusted honey intake (g/1000 kcal per d) instead of consumption frequency of honey. To assess the dose-response association between honey intake (g/1000 kcal per d) and NAFLD, we used restricted cubic spline functions with four knots (at the 10th, 50th, 90th and 95th percentiles of the honey intake distribution)⁽³⁶⁾.

All statistical analyses were performed using SAS software, version 9.4 (SAS Institute Inc.). A two-tailed *P* value <0.05 was considered to be statistically significant.

Results

Table 1 presents age- and sex-adjusted baseline characteristics of participants according to consumption frequency of honey. Participants who consumed more honey had higher age, were

more likely to be women and had lower BMI ($P_{\text{for trend}} < 0.05$). Moreover, they had higher levels of physical activity, total energy intake, dietary pattern scores and alcohol intake ($P_{\text{for trend}} < 0.05$). They were also more likely to have a lower education level and tended to have hypertension, hyperlipidaemia, diabetes and family history of diabetes ($P_{\text{for trend}} < 0.05$).

Table 2 displays age- and sex-adjusted baseline characteristics of participants by NAFLD status. Participants with NAFLD had higher age, tended to be men and had higher BMI ($P < 0.0001$). In addition, they were more physically inactive, had lower total energy intake, were weaker adherence to the healthy dietary pattern and consumed less alcohol ($P < 0.01$). Participants with NAFLD were more likely to be current smokers, had a lower education level and were less likely to be managers ($P < 0.01$). Furthermore, they had more comorbidities and more likely to have a family history of hypertension and diabetes ($P < 0.0001$).

Table 3 shows adjusted OR and 95 % CI for the association of honey consumption frequency with NAFLD. In the age, sex and BMI adjusted model, honey consumption of 2–6 times/week was significantly associated with a lower prevalence of NAFLD (OR 0.80, 95 % CI 0.72, 0.90), while honey consumption of ≥ 1 times/d was not significantly associated with the prevalence of NAFLD (OR 1.01, 95 % CI 0.88, 1.17). After further adjustment for potential confounders, we observed similar results. In the fully adjusted model, the OR were 0.86 (95 % CI 0.77, 0.97) for 2–6 times/week and 1.10 (95 % CI 0.95, 1.27) for ≥ 1 times/d, as compared with those consuming honey ≤ 1 time/week.

No significant interactions between consumption frequency of honey and covariates were found (all $P_{\text{for interaction}} \geq 0.10$). Furthermore, the multicollinearity test showed that all variance

Table 1. Age- and sex-adjusted characteristics of the participants according to consumption frequency of honey (*n* 21 979) (Least square mean values and 95 % confidence intervals and percentages)

Characteristics	Consumption frequency of honey			<i>P</i> _{for trend} *
	≤1 time/week	2–6 times/week	≥1 times/d	
No. of participants	17 369	3037	1573	–
Age (years)				
Mean	37.8	38.3	42.3	<0.0001
95 % CI	37.6, 37.9	37.9, 38.6	41.7, 42.9	
Sex (men)	54.5	37.9	34.0	<0.0001
BMI (kg/m ²)				
Mean	24.0	23.8	23.7	<0.0001
95 % CI	24.0, 24.1	23.7, 23.9	23.5, 23.8	
PA (MET × h/week)				
Mean	10.2	12.0	11.5	<0.001
95 % CI	10.0, 10.4	11.5, 12.6	10.8, 12.3	
Total energy intake (kcal/d)†				
Mean	1972.9	2153.2	2212.3	<0.0001
95 % CI	1964.5, 1981.3	2131.4, 2175.2	2181.1, 2243.9	
Healthy dietary pattern score				
Mean	−0.04	0.11	0.24	<0.0001
95 % CI	−0.06, −0.03	0.07, 0.14	0.19, 0.29	
Sweet dietary pattern score				
Mean	−0.07	0.25	0.27	<0.0001
95 % CI	−0.08, −0.05	0.22, 0.29	0.22, 0.32	
Animal food dietary pattern score				
Mean	−0.04	0.11	0.15	<0.0001
95 % CI	−0.05, −0.02	0.07, 0.14	0.10, 0.20	
Alcohol intake (g/d)				
Mean	1.96	2.15	2.09	0.03
95 % CI	1.93, 2.00	2.07, 2.24	1.99, 2.21	
Smoking status (%)				
Smoker	18.7	12.8	13.0	0.93
Ex-smoker	5.04	3.51	3.61	0.17
Non-smoker	76.3	83.7	83.4	0.53
Education level (≥college)	66.2	68.3	61.0	0.02
Occupation				
Managers	41.2	44.3	38.8	0.34
Professionals	14.7	13.3	13.1	0.80
Other	44.1	42.4	48.1	0.33
Household income (≥10 000 Yuan)	31.7	33.2	32.6	0.0
Hypertension	20.8	17.4	20.5	<0.01
Hyperlipidaemia	42.3	37.6	42.4	0.03
Diabetes	4.38	2.04	1.84	<0.0001
Family history of disease				
CVD	27.2	27.9	31.2	0.81
Hypertension	49.2	50.3	50.0	0.28
Hyperlipidaemia	0.42	0.32	0.27	0.15
Diabetes	26.5	23.9	23.6	<0.0001

MET, metabolic equivalent; PA, physical activity.

* ANCOVA or logistic regression analysis adjusted for age and sex where appropriate.

† To convert kcal to kJ, multiply by 4.184.

inflation factors were <2.0, suggesting that no collinearity was accepted.

The strength of the associations between consumption frequency of honey and NAFLD was largely consistent across BMI subgroups (Fig. 3). In addition, excluding participants with significant alcohol intake did not substantially modify the observed association (online Supplementary Table S1). In a series of additional analyses based on different categorisations, the results were comparable with those of the main analyses (Fig. 4). The association between energy-adjusted honey intake and NAFLD is shown in online Supplementary Table S2. The shape of the association of honey intake with NAFLD is shown in Fig. 5. In the cubic spline model adjusted for the same

covariates in model 3, we found a non-linear association between honey intake and NAFLD (*P*_{for non-linearity} < 0.001), with an inverse association for light to moderate intake, but no association at heavy intake.

Discussion

In this large-scale population-based study, we found that light to moderate honey consumption was inversely associated with NAFLD, whereas heavy honey consumption was not statistically significantly associated with NAFLD. To our knowledge, this is the first report that has examined

Table 2. Age- and sex-adjusted characteristics of the participants according to non-alcoholic fatty liver disease (NAFLD) status (*n* 21 979) (Least square mean values and 95 % confidence intervals and percentages)

Characteristics	NAFLD status		<i>P</i> *
	No	Yes	
No. of participants	15 466	6513	–
Age (years)			
Mean	37.1	40.9	<0.0001
95 % CI	36.9, 37.2	40.6, 41.2	
Sex (men)	40.8	74.3	<0.0001
BMI (kg/m ²)			
Mean	22.9	26.6	<0.0001
95 % CI	22.9, 23.0	26.5, 26.7	
PA (MET × h/week)			
Mean	10.8	9.86	<0.0001
95 % CI	10.6, 11.0	9.55, 10.2	
Total energy intake (kcal/d)†			
Mean	2022.4	1992.2	<0.001
95 % CI	2013.1, 2031.7	1977.7, 2006.8	
Healthy dietary pattern score			
Mean	0.01	−0.04	<0.01
95 % CI	0.00, 0.03	−0.06, −0.01	
Sweet dietary pattern score			
Mean	0.01	−0.02	0.07
95 % CI	−0.01, 0.03	−0.04, 0.01	
Animal food dietary pattern score			
Mean	0.00	−0.01	0.54
95 % CI	−0.02, 0.02	−0.03, 0.02	
Alcohol intake (g/d)			
Mean	2.13	1.72	<0.0001
95 % CI	2.09, 2.16	1.68, 1.77	
Smoking status			
Smoker	13.6	26.7	<0.001
Ex-smoker	3.73	7.12	0.41
Non-smoker	82.7	66.2	<0.001
Education level (≥college)	68.0	61.6	<0.001
Occupation			
Managers	42.0	40.2	<0.01
Professionals	14.0	15.3	0.42
Other	44.0	44.5	0.02
Household income (≥10 000 Yuan)	32.3	31.1	0.09
Hypertension	12.9	37.9	<0.0001
Hyperlipidaemia	31.4	65.8	<0.0001
Diabetes	1.84	8.71	<0.0001
Family history of disease			
CVD	26.6	30.1	0.14
Hypertension	47.5	54.1	<0.0001
Hyperlipidaemia	0.36	0.48	0.36
Diabetes	24.0	30.6	<0.0001

MET, metabolic equivalent; PA, physical activity.

* ANCOVA or logistic regression analysis adjusted for age and sex where appropriate.

† To convert kcal to kJ, multiply by 4.184.

Table 3. Association of honey consumption frequency with non-alcoholic fatty liver disease (NAFLD) in the Tianjin Chronic Low-grade Systemic Inflammation and Health (TCLSIH) study (*n* 21 979) (Odds ratios and 95 % confidence intervals)

Logistic regression models	Consumption frequency of honey				<i>P</i> _{for trend} *	
	≤1 time/week	2–6 times/week		≥1 times/d		
	OR	OR	95 % CI	OR	95 % CI	
No. of participants	17 369	3037		1573	–	
No. of NAFLD	5416	691		406	–	
Model 1	1.00 (reference)	0.80	0.72, 0.90	1.01	0.88, 1.17	0.09
Model 2	1.00 (reference)	0.86	0.76, 0.96	1.09	0.94, 1.26	0.78
Model 3	1.00 (reference)	0.86	0.77, 0.97	1.10	0.95, 1.27	0.90

* Obtained by using logistic regression analysis. Model 1 was adjusted for age, sex and BMI. Model 2 was adjusted for age, sex, BMI, smoking status, alcohol intake, education level, occupation, household income, physical activity, family history of disease (including CVD, hypertension, hyperlipidaemia and diabetes), hypertension, hyperlipidaemia, diabetes and total energy intake. Model 3 was adjusted for the same variables as in model 2 and further for three main dietary pattern scores (honey intake was not included in the calculation).




Fig. 3. Association of honey consumption frequency with non-alcoholic fatty liver disease (NAFLD) according to BMI (<24.0 or ≥24.0 kg/m²). Adjusted for age, sex, BMI, smoking status, alcohol intake, education level, occupation, household income, physical activity, family history of disease (including CVD, hypertension, hyperlipidaemia and diabetes), hypertension, hyperlipidaemia, diabetes, total energy intake and three main dietary pattern scores (honey intake was not included in the calculation).




Fig. 4. Association of honey consumption frequency with non-alcoholic fatty liver disease (NAFLD) in. Adjusted for age, sex, BMI, smoking status, alcohol intake, education level, occupation, household income, physical activity, family history of disease (including CVD, hypertension, hyperlipidaemia and diabetes), hypertension, hyperlipidaemia, diabetes, total energy intake and three main different categorisation analysis dietary pattern scores (honey intake was not included in the calculation).

the association of habitual honey consumption frequency and NAFLD.

In the present study, we used a DAG to determine covariate adjustment sets for minimising confounding bias⁽³³⁾. The DAG approach can offer systematic representations of causal associations, thereby making robust inferences in a causal framework⁽³⁷⁾. In addition, the DAG approach helps to avoid collider bias and overadjustment bias^(33,38). After adjusting for confounding factors identified by the DAG (model 3), the results were similar to model 1 and model 2 (Table 3). Moreover, similar associations were observed among lean (BMI < 24.0 kg/m²) and overweight (BMI ≥ 24.0 kg/m²) participants. Therefore, the observed association between honey consumption frequency and NAFLD was not confounded by covariates.

Previous animal studies have reported that honey intake could reverse the formation of hepatic steatosis⁽¹⁵⁾. However,

no studies assessed the effects of dietary honey intake on NAFLD in humans. In this study, we observed an inverse association between honey consumption of 2–6 times/week and NAFLD in the general population. This inverse association partially confirms previous findings from animal studies. However, we observed no significant association between honey consumption of ≥1 times/d and NAFLD. Future studies should investigate whether similar results can be found in other populations.

The significant inverse association between light to moderate honey consumption and NAFLD is biologically plausible. First, honey is rich in phenolic acids, flavonoids and phenol contents^(39,40). Studies have shown that phenolic acids and flavonoids could ameliorate NAFLD by activating the adiponectin/AMPK pathway and suppressing the nuclear factor-kappaB pathway^(41,42). Moreover, cross-sectional studies found that higher phenolic acid and flavonoid consumption was associated with a lower likelihood of NAFLD^(43,44). Second, animal experiments suggest that honey could inhibit the toll-like receptor 4 pathway via suppression of phosphorylated nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha⁽⁴⁵⁾. Emerging evidence has shown that the toll-like receptor 4 signalling pathway is involved in the development and progression of NAFLD⁽⁴⁶⁾. Third, honey contains a number of vitamins, minerals and antioxidant enzymes. Therefore, honey intake might prevent NAFLD by its antioxidant properties⁽⁴⁷⁾. Epidemiological evidence also suggested that daily intake of vitamins and minerals was inversely associated with the prevalence of NAFLD^(48,49).

Interestingly, no significant association between heavy honey consumption, defined as ≥1 times/d, and NAFLD was found. Studies have suggested that fructose promotes liver lipogenesis, which can lower insulin sensitivity and lead to NAFLD⁽¹⁷⁾. Therefore, the possible harmful effect of fructose in honey on NAFLD may have been offset the possible protective effect of honey on NAFLD.

To our knowledge, this is the first observational study that has investigated the association between honey consumption frequency and NAFLD in the general population. The strengths of this study are the large sample size, comprehensive capture of baseline dietary and lifestyle variables and adjusting for a number of confounders identified by the DAG. In addition, honey was widely consumed in our study population⁽⁶⁾, which gave us a unique opportunity to examine the independent effect of honey on NAFLD.

The study also has limitations. First, self-reported honey information is subject to measurement errors. However, this misclassification would be expected to bias the estimates towards the null⁽²⁵⁾. Second, different types or brands of honey were not assessed in this study, and therefore, we may have missed the effect of specific honeys on NAFLD. Third, NAFLD was diagnosed using abdominal ultrasound rather than liver biopsy (the gold standard). However, previous studies showed that ultrasonography had high sensitivity and specificity for NAFLD diagnosis compared with the gold standard⁽⁵⁰⁾. Moreover, ultrasonography is widely used in large-scale epidemiological studies due to its non-invasiveness and accessibility. Fourth, as with any epidemiological study, we cannot completely rule out the possibility of residual or unmeasured




Fig. 5. Multivariable dose–response association between honey intake (g/1000 kcal per d) and non-alcoholic fatty liver disease (NAFLD). Adjusted for age, sex, BMI, smoking status, alcohol intake, education level, occupation, household income, physical activity, family history of disease (including CVD, hypertension, hyperlipidaemia and diabetes), hypertension, hyperlipidaemia, diabetes, total energy intake and three main dietary pattern scores (honey intake was not included in the calculation). The reference value for honey intake (g/1000 kcal per d) was set at the median intake. The four knots were set at the 10th, 50th, 90th and 95th percentiles of the honey intake (g/1000 kcal per d) distribution. —, Estimation; ---, lower confidence limit; ---, upper confidence limit; ●●●, knots.

confounding. Finally, because of the cross-sectional nature of this study design, we could not make the causal inference. Prospective cohort studies are therefore necessary to evaluate the longitudinal association between honey consumption and NAFLD.

Conclusion

In conclusion, our data show a U-shaped association between consumption frequency of honey and NAFLD in the general adult population. Future study is needed to replicate our findings and disentangle the underlying mechanisms.

Acknowledgements

The authors gratefully acknowledge all the people who have made this study.

This study was supported by grants from the National Natural Science Foundation of China (nos. 81974521, 91746205, 81673166, and 81372118) and the Tianjin Natural Science Foundation Key Project (no. 19JCZDJC33500).

S. Z. analysed the data and wrote the paper. S. Z., X. W., S. B., Q. Z., L. L., G. M., Z. Y., H. W., Y. G., Y. W., S. S., X. W., M. Z., Q. J. and K. S. conducted the research. K. N. and X. W. designed the research and had primary responsibility for the final content. All authors had access to the study data and reviewed and approved the final manuscript.

The authors declare that there are no conflicts of interest.

Supplementary material

For supplementary materials referred to in this article, please visit <https://doi.org/10.1017/S0007114520003190>

References

1. Povsic M, Wong OY, Perry R, *et al.* (2019) A structured literature review of the epidemiology and disease burden of non-alcoholic steatohepatitis (NASH). *Adv Ther* **36**, 1574–1594.
2. Younossi ZM (2019) Non-alcoholic fatty liver disease – a global public health perspective. *J Hepatol* **70**, 531–544.
3. Takahashi Y & Fukusato T (2014) Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *World J Gastroenterol* **20**, 15539–15548.
4. Danford CJ & Lai M (2019) NAFLD: a multisystem disease that requires a multidisciplinary approach. *Frontline Gastroenterol* **10**, 328–329.
5. Alvarez-Suarez JM, Gasparrini M, Forbes-Hernandez TY, *et al.* (2014) The composition and biological activity of honey: a focus on Manuka honey. *Foods* **3**, 420–432.
6. Zhang S, Lu Z, Tian C, *et al.* (2020) Associations between honey consumption and prehypertension in adults aged 40 years and older. *Clin Exp Hypertens* **42**, 420–427.
7. Ajibola A, Chamunorwa JP & Erlwanger KH (2012) Nutraceutical values of natural honey and its contribution to human health and wealth. *Nutr Metab* **9**, 61.
8. Ramli NZ, Chin KY, Zarkasi KA, *et al.* (2018) A review on the protective effects of honey against metabolic syndrome. *Nutrients* **10**, 1009.
9. Badolato M, Carullo G, Cione E, *et al.* (2017) From the hive: honey, a novel weapon against cancer. *Eur J Med Chem* **142**, 290–299.
10. Al-Waili N, Salom K, Al-Ghamdi A, *et al.* (2013) Honey and cardiovascular risk factors, in normal individuals and in patients with diabetes mellitus or dyslipidemia. *J Med Food* **16**, 1063–1078.
11. Gao B & Tsukamoto H (2016) Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe? *Gastroenterology* **150**, 1704–1709.
12. Polimeni L, Del Ben M, Baratta F, *et al.* (2015) Oxidative stress: new insights on the association of non-alcoholic fatty liver disease and atherosclerosis. *World J Hepatol* **7**, 1325–1336.

13. Abdulrhman MM, El-Hefnawy MH, Aly RH, *et al.* (2013) Metabolic effects of honey in type 1 diabetes mellitus: a randomized crossover pilot study. *J Med Food* **16**, 66–72.
14. Nazir L, Samad F, Haroon W, *et al.* (2014) Comparison of glycaemic response to honey and glucose in type 2 diabetes. *J Pak Med Assoc* **64**, 69–71.
15. Samat S, Kanyan Enchang F, Nor Hussein F, *et al.* (2017) Four-week consumption of Malaysian honey reduces excess weight gain and improves obesity-related parameters in high fat diet induced obese rats. *Evid Based Complement Alternat Med* **2017**, 1342150.
16. Kamal MA & Klein P (2011) Determination of sugars in honey by liquid chromatography. *Saudi J Biol Sci* **18**, 17–21.
17. Jensen T, Abdelmalek MF, Sullivan S, *et al.* (2018) Fructose and sugar: a major mediator of non-alcoholic fatty liver disease. *J Hepatol* **68**, 1063–1075.
18. Vos MB & Lavine JE (2013) Dietary fructose in nonalcoholic fatty liver disease. *Hepatology* **57**, 2525–2531.
19. Zhang S, Gu Y, Wang L, *et al.* (2019) Association between dietary raw garlic intake, newly diagnosed nonalcoholic fatty liver disease: a population-based study. *Eur J Endocrinol* **181**, 591–602.
20. Zhang S, Fu J, Zhang Q, *et al.* (2019) Association between nut consumption and non-alcoholic fatty liver disease in adults. *Liver Int* **39**, 1732–1741.
21. Vittinghoff E & McCulloch CE (2007) Relaxing the rule of ten events per variable in logistic and Cox regression. *Am J Epidemiol* **165**, 710–718.
22. National Workshop on Fatty L, Alcoholic Liver Disease CSoHCMA & Fatty Liver Expert Committee CMDA (2018) [Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update]. *Zhonghua Gan Zang Bing Za Zhi* **26**, 195–203.
23. Yang Y (2009) *China Food Composition*, 2nd ed. Beijing: Pecking University Medical Press.
24. Kobayashi S, Murakami K, Sasaki S, *et al.* (2011) Comparison of relative validity of food group intakes estimated by comprehensive and brief-type self-administered diet history questionnaires against 16 d dietary records in Japanese adults. *Public Health Nutr* **14**, 1200–1211.
25. Willett W (2013) *Nutritional Epidemiology*, 3rd ed. New York: Oxford University Press.
26. Zhang S, Kumari S, Gu Y, *et al.* (2020) Honey consumption is inversely associated with prediabetes among Chinese adults: results from the TCLSIH Cohort Study. *Br J Nutr* (publication ahead of print version 3 March 2020).
27. Baesens B (2014) *Analytics in a Big Data World: The Essential Guide to Data Science and Its Applications*. Hoboken, NJ: John Wiley & Sons, Inc.
28. Craig CL, Marshall AL, Sjostrom M, *et al.* (2003) International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc* **35**, 1381–1395.
29. Chobanian AV, Bakris GL, Black HR, *et al.* (2003) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* **289**, 2560–2572.
30. Expert Panel on Detection E & Treatment of High Blood Cholesterol in A (2001) Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* **285**, 2486–2497.
31. American Diabetes Association (2012) Diagnosis and classification of diabetes mellitus. *Diabetes Care* **35**, Suppl. 1, S64–S71.
32. VanderWeele TJ, Hernan MA & Robins JM (2008) Causal directed acyclic graphs and the direction of unmeasured confounding bias. *Epidemiology* **19**, 720–728.
33. Shrier I & Platt RW (2008) Reducing bias through directed acyclic graphs. *BMC Med Res Methodol* **8**, 70.
34. Textor J, Hardt J & Knuppel S (2011) DAGitty: a graphical tool for analyzing causal diagrams. *Epidemiology* **22**, 745.
35. Zhou BF & Cooperative Meta-Analysis Group of the Working Group on Obesity in China (2002) Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults – study on optimal cut-off points of body mass index and waist circumference in Chinese adults. *Biomed Environ Sci* **15**, 83–96.
36. Desquilbet L & Mariotti F (2010) Dose–response analyses using restricted cubic spline functions in public health research. *Stat Med* **29**, 1037–1057.
37. Textor J, van der Zander B, Gilthorpe MS, *et al.* (2016) Robust causal inference using directed acyclic graphs: the R package ‘dagitty’. *Int J Epidemiol* **45**, 1887–1894.
38. Rohrig N, Strobl R, Muller M, *et al.* (2014) Directed acyclic graphs helped to identify confounding in the association of disability and electrocardiographic findings: results from the KORA-Age study. *J Clin Epidemiol* **67**, 199–206.
39. Ahmed AYBH, Obbed MS, Wabaidur SM, *et al.* (2014) High-performance liquid chromatography analysis of phenolic acid, flavonoid, and phenol contents in various natural Yemeni honeys using multi-walled carbon nanotubes as a solid-phase extraction adsorbent. *J Agric Food Chem* **62**, 5443–5450.
40. Pyrzyńska K & Biesaga M (2009) Analysis of phenolic acids and flavonoids in honey. *Trends Anal Chem* **28**, 893–902.
41. Akhlaghi M (2016) Non-alcoholic fatty liver disease: beneficial effects of flavonoids. *Phytother Res* **30**, 1559–1571.
42. Madushani Herath K, Cho J, Kim A, *et al.* (2018) Phenolic acid and flavonoid-rich fraction of *Sasa quelpaertensis* Nakai leaves prevent alcohol induced fatty liver through AMPK activation. *J Ethnopharmacol* **224**, 335–348.
43. Mazidi M, Katsiki N & Banach M (2019) A higher flavonoid intake is associated with less likelihood of nonalcoholic fatty liver disease: results from a multiethnic study. *J Nutr Biochem* **65**, 66–71.
44. Salomone F, Ivancovsky-Wajcman D, Fliss-Isakov N, *et al.* (2020) Higher phenolic acid intake independently associates with lower prevalence of insulin resistance and non-alcoholic fatty liver disease. *JHEP Rep* **2**, 100069.
45. Gasparrini M, Afrin S, Forbes-Hernandez TY, *et al.* (2018) Protective effects of Manuka honey on LPS-treated RAW 264.7 macrophages. Part 2: control of oxidative stress induced damage, increase of antioxidant enzyme activities and attenuation of inflammation. *Food Chem Toxicol* **120**, 578–587.
46. Liu J, Zhuang ZJ, Bian DX, *et al.* (2014) Toll-like receptor-4 signalling in the progression of non-alcoholic fatty liver disease induced by high-fat and high-fructose diet in mice. *Clin Exp Pharmacol Physiol* **41**, 482–488.
47. Khan SU, Anjum SI, Rahman K, *et al.* (2018) Honey: single food stuff comprises many drugs. *Saudi J Biol Sci* **25**, 320–325.
48. Ivancovsky-Wajcman D, Fliss-Isakov N, Salomone F, *et al.* (2019) Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease. *Dig Liver Dis* **51**, 1698–1705.
49. Tayyem RF, Al-Dayyat HM & Rayyan YM (2019) Relationship between lifestyle factors and nutritional status and non-alcoholic fatty liver disease among a group of adult Jordanians. *Arab J Gastroenterol* **20**, 44–49.
50. Hernaez R, Lazo M, Bonekamp S, *et al.* (2011) Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. *Hepatology* **54**, 1082–1090.